Loading...

Editas Medicine

DB:8EM
Snowflake Description

Excellent balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8EM
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Editas Medicine, Inc. operates as a clinical stage genome editing company. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Editas Medicine has significant price volatility in the past 3 months.
8EM Share Price and Events
7 Day Returns
7.6%
DB:8EM
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-7.2%
DB:8EM
-5.6%
DE Biotechs
-4.5%
DE Market
8EM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Editas Medicine (8EM) 7.6% 21.1% 29.1% -7.2% -23.9% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 8EM underperformed the Biotechs industry which returned -5.6% over the past year.
  • 8EM underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
8EM
Industry
5yr Volatility vs Market

Value

 Is Editas Medicine undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Editas Medicine. This is due to cash flow or dividend data being unavailable. The share price is €24.34.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Editas Medicine's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Editas Medicine's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:8EM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.33
NasdaqGS:EDIT Share Price ** NasdaqGS (2019-04-25) in USD $27.16
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Editas Medicine.

DB:8EM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:EDIT Share Price ÷ EPS (both in USD)

= 27.16 ÷ -2.33

-11.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Editas Medicine is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Editas Medicine is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Editas Medicine's expected growth come at a high price?
Raw Data
DB:8EM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-9.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Editas Medicine, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Editas Medicine's assets?
Raw Data
DB:8EM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.84
NasdaqGS:EDIT Share Price * NasdaqGS (2019-04-25) in USD $27.16
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:8EM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:EDIT Share Price ÷ Book Value per Share (both in USD)

= 27.16 ÷ 4.84

5.61x

* Primary Listing of Editas Medicine.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Editas Medicine is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Editas Medicine's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Editas Medicine has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Editas Medicine expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-9.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Editas Medicine expected to grow at an attractive rate?
  • Unable to compare Editas Medicine's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Editas Medicine's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Editas Medicine's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:8EM Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:8EM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -9.3%
DB:8EM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:8EM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:8EM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 68 -216 2
2022-12-31 28 -151 2
2021-12-31 28 -166 3
2020-12-31 37 -143 -160 6
2019-12-31 32 -115 -136 6
DB:8EM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 32 -46 -110
2018-09-30 29 -72 -121
2018-06-30 21 -92 -132
2018-03-31 17 -102 -120
2017-12-31 14 -9 -120
2017-09-30 11 2 -124
2017-06-30 6 13 -118
2017-03-31 6 29 -111
2016-12-31 6 -50 -97
2016-09-30 6 -45 -71
2016-06-30 6 -39 -57
2016-03-31 2 -9 -86

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Editas Medicine is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Editas Medicine's revenue is expected to grow by 9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:8EM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Editas Medicine Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8EM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.71 -1.78 -3.25 3.00
2022-12-31 -2.58 -1.81 -3.12 5.00
2021-12-31 -3.01 -2.90 -3.18 5.00
2020-12-31 -3.10 -2.60 -3.92 7.00
2019-12-31 -2.82 -2.50 -3.34 7.00
DB:8EM Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.33
2018-09-30 -2.65
2018-06-30 -2.99
2018-03-31 -2.81
2017-12-31 -2.98
2017-09-30 -3.20
2017-06-30 -3.17
2017-03-31 -3.09
2016-12-31 -3.02
2016-09-30 -2.93
2016-06-30 -3.59
2016-03-31 -11.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Editas Medicine will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Editas Medicine's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Editas Medicine has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Editas Medicine performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Editas Medicine's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Editas Medicine does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Editas Medicine's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Editas Medicine's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Editas Medicine's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Editas Medicine Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8EM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 31.94 -109.95 55.01
2018-09-30 29.49 -121.09 55.52
2018-06-30 21.25 -132.45 54.82
2018-03-31 16.97 -120.17 52.40
2017-12-31 13.73 -120.32 50.50
2017-09-30 10.96 -123.51 49.86
2017-06-30 5.64 -117.93 48.52
2017-03-31 5.93 -110.54 48.79
2016-12-31 6.05 -97.23 46.26
2016-09-30 5.95 -70.59 40.55
2016-06-30 5.66 -57.08 33.46
2016-03-31 2.43 -85.70 24.58
2015-12-31 1.63 -73.29 18.10
2015-09-30 0.84 -66.07 13.55
2015-06-30 0.17 -62.00 11.23
2015-03-31 -16.86 9.44
2014-12-31 -13.99 7.65
2013-12-31 -5.35 3.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Editas Medicine has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Editas Medicine has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Editas Medicine improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Editas Medicine's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Editas Medicine has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Editas Medicine's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Editas Medicine's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Editas Medicine is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Editas Medicine's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Editas Medicine's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 11.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Editas Medicine Company Filings, last reported 3 months ago.

DB:8EM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 236.16 32.42 368.96
2018-09-30 224.45 32.69 337.49
2018-06-30 231.33 32.94 344.08
2018-03-31 247.52 33.19 358.82
2017-12-31 208.08 40.93 329.14
2017-09-30 177.79 33.67 295.69
2017-06-30 185.00 48.88 324.80
2017-03-31 206.46 48.93 351.55
2016-12-31 134.61 45.10 185.32
2016-09-30 170.18 32.05 199.87
2016-06-30 187.33 22.68 217.65
2016-03-31 201.36 11.65 229.20
2015-12-31 116.80 0.00 143.18
2015-09-30 127.48 1.83 155.30
2015-06-30 14.10 1.17 47.04
2015-03-31 5.48 0.41 10.62
2014-12-31 5.48 0.41 10.62
2013-12-31 0.35 0.00 2.01
  • Editas Medicine's level of debt (13.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.3% vs 13.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Editas Medicine has sufficient cash runway for more than 3 years based on current free cash flow.
  • Editas Medicine has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 48.5% each year.
X
Financial health checks
We assess Editas Medicine's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Editas Medicine has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Editas Medicine's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Editas Medicine dividends.
If you bought €2,000 of Editas Medicine shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Editas Medicine's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Editas Medicine's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:8EM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:8EM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Editas Medicine has not reported any payouts.
  • Unable to verify if Editas Medicine's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Editas Medicine's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Editas Medicine has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Editas Medicine's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Editas Medicine afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Editas Medicine has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Editas Medicine's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Cindy Collins
AGE 60
TENURE AS CEO 0.2 years
CEO Bio

Ms. Cynthia L. Collins, also Known as Cindy, has been a Director of Editas Medicine, Inc. since December 10, 2018 and its Interim Chief Executive Officer since February 2019. She has been a Director of DermTech, Inc. since May 2018. Ms. Collins served as the Chief Executive Officer at Human Longevity, Inc. from January 09, 2017 to December 1, 2017. Ms. Collins served as an Advisor at Phase Holographic Imaging PHI AB (publ). She served as the Chief Executive Officer and President of GenVec, Inc. from May 23, 2012 to September 2013. She served as Chief Executive Officer of GE’sClarient Diagnostics, Inc. Ms. Collins served as Group Vice President of Cellular Analysis Business Group at Beckman Coulter, Inc. from May 21, 2007 to 2011. She joined Beckman Coulter from Sequoia Pharmaceuticals, Inc., where she served as Chief Executive Officer and President. She served as the President of Clinical MicroSensors, Inc., a wholly owned subsidiary of Motorola where she directed the development and commercialization of molecular diagnostic microarray products. She served as Vice President and General Manager level positions for the Gene and Cell Therapy, Transfusion Therapies and BioScience divisions at Baxter Healthcare Corporation. She spent over 17 years at Baxter Healthcare in a variety of executive roles, including President of Global Oncology and Vice President of Strategy and Portfolio Management of BioScience and six years with Abbott Laboratories in a series of operational assignments. She serves as a Member of The Adviser Board at Phase Holographic Imaging PHI AB (publ). She serves as a Director of Phase Holographic Imaging PHI AB (publ). She has been a Director of Biohealth Innovation since February 11, 2013. She served as a Director of GenVec, Inc. since May 23, 2012. Ms. Collins received her undergraduate degree in microbiology in 1980 from the University of Illinois and her MBA from the University of Chicago Graduate School of Business in 1988.

CEO Compensation
  • Insufficient data for Cindy to compare compensation growth.
  • Insufficient data for Cindy to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Editas Medicine management team in years:

6.3
Average Tenure
60
Average Age
  • The average tenure for the Editas Medicine management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Charlie Albright

TITLE
Chief Scientific Officer
COMPENSATION
$1M
AGE
60
TENURE
2.7 yrs

Cindy Collins

TITLE
Interim CEO & Director
AGE
60
TENURE
0.2 yrs

Feng Zhang

TITLE
Co-Founder & Scientific Advisory Board Member
TENURE
6.3 yrs

George Church

TITLE
Co-Founder & Scientific Advisory Board Member
AGE
64
TENURE
6.3 yrs

J. Joung

TITLE
Co-Founder & Scientific Advisory Board Member
TENURE
6.3 yrs

David Liu

TITLE
Co-Founder & Scientific Advisory Board Member
TENURE
6.3 yrs

Eric Ek

TITLE
Interim CFO

Vic Myer

TITLE
Chief Technology Officer
TENURE
4 yrs

Mark Mullikin

TITLE
Senior Director of Finance & Investor Relations

Charlene Stern

TITLE
Vice President of Legal
Board of Directors Tenure

Average tenure and age of the Editas Medicine board of directors in years:

1.5
Average Tenure
59
Average Age
  • The average tenure for the Editas Medicine board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jim Mullen

TITLE
Chairman of the Board
AGE
59
TENURE
1.1 yrs

Cindy Collins

TITLE
Interim CEO & Director
AGE
60
TENURE
0.3 yrs

Feng Zhang

TITLE
Co-Founder & Scientific Advisory Board Member

George Church

TITLE
Co-Founder & Scientific Advisory Board Member
AGE
64

J. Joung

TITLE
Co-Founder & Scientific Advisory Board Member

David Liu

TITLE
Co-Founder & Scientific Advisory Board Member

Akshay Vaishnaw

TITLE
Director
COMPENSATION
$163K
AGE
55
TENURE
2.8 yrs

Andrew Hirsch

TITLE
Director
COMPENSATION
$246K
AGE
47
TENURE
1.9 yrs

Terry Flotte

TITLE
Scientific Advisory Board Member

Charles Gersbach

TITLE
Scientific Advisory Board Member
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Editas Medicine insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Mar 19 Buy Jessica Hopfield Individual 05. Mar 19 05. Mar 19 10,200 €21.19 €216,106
22. May 18 Buy James Mullen Individual 18. May 18 18. May 18 10,000 €32.31 €323,100
21. May 18 Buy Jessica Hopfield Individual 17. May 18 17. May 18 6,700 €31.60 €211,739
X
Management checks
We assess Editas Medicine's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Editas Medicine has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Details
Name: Editas Medicine, Inc.
8EM
Exchange: DB
Founded: 2013
$1,190,493,876
48,822,251
Website: http://www.editasmedicine.com
Address: Editas Medicine, Inc.
11 Hurley Street,
Cambridge,
Massachusetts, 02141,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS EDIT Common Stock Nasdaq Global Select US USD 03. Feb 2016
DB 8EM Common Stock Deutsche Boerse AG DE EUR 03. Feb 2016
LSE 0IFK Common Stock London Stock Exchange GB USD 03. Feb 2016
Number of employees
Current staff
Staff numbers
133
Editas Medicine employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:45
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/22
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.